Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2016 (2016), Article ID 2579626, 7 pages
http://dx.doi.org/10.1155/2016/2579626
Research Article

Association of eNOS Gene Polymorphisms G894T and T-786C with Risk of Hepatorenal Syndrome

1Department of Gastroenterology, Faculty of Medicine, Inonu University, 44280 Malatya, Turkey
2Department of Internal Medicine, Faculty of Medicine, Inonu University, 44280 Malatya, Turkey
3Department of Medical Biology and Genetics, Faculty of Medicine, Inonu University, 44280 Malatya, Turkey
4Department of Biostatistics, Faculty of Medicine, Inonu University, 44280 Malatya, Turkey
5Department of Biochemistry, Faculty of Medicine, Inonu University, 44280 Malatya, Turkey

Received 9 May 2016; Accepted 10 July 2016

Academic Editor: Alessandro Passardi

Copyright © 2016 Yuksel Seckin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. There are no studies investigating the relationship between endothelial nitric oxide synthase (eNOS) gene polymorphisms and hepatorenal syndrome (HRS). Aim. The purpose of this study is to elucidate whether eNOS gene polymorphisms (G894T and T-786C) play a role in the development of type-2 HRS. Methods. This study was carried out in a group of 92 patients with cirrhosis (44 patients with type-2 HRS and 48 without HRS) and 50 healthy controls. Polymorphisms were determined by polymerase chain reaction (PCR) and melting curve analysis. Results. We did not find any significant difference in allele and genotype distributions of the eNOS -T-786C polymorphism among the groups (). However, the frequency of GT (40.9%) and TT (13.6%) genotypes and mutant allele T (34.1%) for the eNOS G894T polymorphism were significantly higher ( and , resp.) in the HRS group than in both the stable cirrhosis (14.6%, 4.2%, and 11.5%, resp.) and the control (22.0%, 2.0%, and 13.0%, resp.) groups. Conclusion. The occurrence of mutant genotypes (GT/TT) and mutant allele T in eNOS -G894T polymorphisms should be considered as a potential risk factor in cirrhotic patients with HRS.